Bacteria: Gram-negative

Escherichia coli

E. coli

General medical information for education only, not medical advice. Treatment considerations summarize published guidance at drug-class level; therapy is chosen by the treating clinician using susceptibility results, local resistance patterns and current guidelines.

Overview

A normal inhabitant of the human gut and the most common cause of urinary tract infection. Extraintestinal strains cause cystitis, pyelonephritis and bloodstream infection; separate diarrheagenic strains cause gastrointestinal illness (see Diarrheagenic E. coli).

Infections

Cystitis, pyelonephritis, urosepsis, intra-abdominal infection, bloodstream infection, neonatal meningitis.

Signs and symptoms

Urinary: dysuria, frequency, urgency, suprapubic or flank pain, fever. Bloodstream infection: fever, rigors, hypotension.

Antibiotic and antimicrobial resistance

Extended-spectrum beta-lactamases (CTX-M, SHV, TEM) (ESBL genes) are increasingly common; carbapenemases (carbapenemases) and plasmid-mediated quinolone resistance (qnr) also occur.

Treatment considerations

Uncomplicated cystitis is commonly treated with nitrofurantoin, trimethoprim-sulfamethoxazole or fosfomycin, chosen by local resistance rates. Pyelonephritis and systemic infection need agents with tissue and blood levels, guided by susceptibility testing; ESBL-producing strains often require a carbapenem.

Rod-shaped Escherichia coli bacteria, colorized electron micrograph
Escherichia coli, low-temperature electron micrograph (colorized). USDA ARS (E. Erbe, C. Pooley); public domain. Image source
Gram-negative rods, schematic
Gram-negative rods. Schematic, not to scale; InnovexLab.

Sources

  1. CDC. E. coli infection.
  2. CDC. ESBL-producing Enterobacterales.
  3. IDSA. Complicated Urinary Tract Infections guideline.
  4. IDSA. Asymptomatic Bacteriuria guideline.
  5. IDSA. Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.

Sources accessed November 2026. Links open external sites that InnovexLab does not control.

Medical disclaimer

This page is general educational information summarized from published public-health and professional-society guidance. It is not medical advice, a diagnosis or a treatment recommendation, and reading it does not create a clinician–patient relationship with InnovexLab. Decisions about testing, diagnosis and treatment belong to the treating clinician, using the patient’s history and examination, laboratory and susceptibility results, local resistance patterns and current guidelines. Guidance changes over time; consult the original sources for the latest version. InnovexLab provides this information as is and does not warrant that it is complete or current.

Patients with questions about their health should contact their own healthcare provider. In an emergency, call 911.

Sources, image credits and editorial policy

Discuss a testing program with InnovexLab

Review the panel that fits your patients, its specimen requirements, and how results and billing work.